Stratified administration of serotonin 5-HT3 receptor antagonists (setrons) for chemotherapy-induced emesis: Economic implications

PharmacoEconomics

Volumn 18, Issue 6, 2000, Pages 533-556

  Sanchez, L A ^a   Holdsworth, M ^b   Bartel, S B ^c  

^a PE Applications Inc   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOCETAXEL; DOLASETRON MESILATE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; GEMCITABINE; GRANISETRON; HYDROXYUREA; IDARUBICIN; METHOTREXATE; ONDANSETRON; PACLITAXEL; PROCARBAZINE; SEROTONIN 3 ANTAGONIST; STREPTOZOCIN; TIOGUANINE; UNINDEXED DRUG; VINBLASTINE;

ACUTE DISEASE; ANTIEMETIC ACTIVITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDICATION; ECONOMIC ASPECT; GROUPS BY AGE; HEALTH CARE ORGANIZATION; HUMAN; MEDICAL LITERATURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; UNITED STATES;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; HUMANS; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN ANTAGONISTS; VOMITING;

EID: 0034523098     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200018060-00002     Document Type: Review

References (112)

1. Proposal for classifying the acute emetogenicity of cancer chemotherapy
2. Controlling emesis in patients receiving cancer chemotherapy
3. Ondansetron: A new entity in emesis control
4. Product information
5. Ondansetron. Therapeutic use as an antiemetic
6. Ondansetron: An update of its therapeutic use in chemotherapy induced and postoperative nausea and vomiting
7. Dose-ranging evaluation of the serotonin antagonist GRC507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy
8. Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting
9. Double-blind, dosefinding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis
10. Comparison of two different doses of ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced emesis
11. A multicenter, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis
12. Cancer
13. Comparison of 16mg vs 32mg ondansetron and dexamethasone in patients receiving cisplatin
14. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis
15. Randomized phase II trial comparing two versus three doses of ondansetron when used with dexamethasone in patients receiving cisplatin > 100 mg/m2
16. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting
17. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: A multicentre double-blind, randomised, parallel-group study
18. Comparison of the antiemetic efficacy of different doses of ondansetron, given as either a continuous infusion of a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study
19. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two singledose regimens in the prevention of cisplatin-induced nausea and vomiting
20. Etude randomisee en double-insu comparant l'efficacite de l'ondansetron selon deux modes d'administration: Injection unique et perfusion continue
21. Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen
22. A randomized, double-blind, comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high dose cisplatin-induced emesis
23. Prevention of cisplatin-induced emesis: A double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone
24. Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron?
25. Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naïve and previously treated patients
26. Phase III double-blind comparison of dolasetron mesylate and ondansetron: An evaluation of the additive role of dexamethasone in the prevention of emetogenic chemotherapy
27. A randomized doubleblind crossover of ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy induced nausea and vomiting in pediatric patients with malignancies
28. Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer
29. A randomized, double-blind, parallel-group study to compare the efficacy and safety of ondansetron (GR38032F) plus dexamethasone with metoclopramide plus dexamethasone in the prophylaxis of nausea and emesis by carboplatin chemotherapy
30. Low-dose intravenous ondansetron (8 mg) plus dexamethasone: An effective regimen for the control of carboplatin-induced emesis
31. The antiemetic efficacy of intravenous ondansetron (OND) at conventional versus low dose in women with early stage breast cancer
32. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: A phase III trial by the National Cancer Institute of Canada Clinical Trial Group
33. Granisetron IV compared with ondansetron IV plus tablets in the prevention of nausea and vomiting induced by a moderately emetogenic chemotherapy regimen: A randomized cross-over study
34. 5HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy - A randomised study
35. The 5-HT3-receptor antagonists in the prevention of acute and delayed emesis induced by standard or accelerated chemotherapy for breast cancer
36. A comparison of oral ondansetron and intravenous granisetron for the prevention of nausea and emesis associated with cisplatin-based chemotherapy
37. A multicenter, double-blind comparison of i.v. and oral administration of ondansetron plus dexamethasone for acute cisplatin-induced emesis
38. Efficacy of oral ondansetron and dexamethasone in prevention of nausea and vomiting associated with moderately-high and highly emetogenic chemotherapy
39. A multicenter, double-blind, randomized comparison of oral ondansetron 8mg b.i.d., 24mg q.d., and 32mg q.d. in the prevention of nausea and vomiting associated with highly emetogenic chemotherapy
40. Oral ondansetron and intravenous dexamethasone in the prevention of cisplatininduced emesis
41. Oral ondansetron 8 mg bid is as effective as 8 mg tid in prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy
42. Comparison of different schedules of ondansetron (GR 38032F) administration during cisplatin-based chemotherapy; A randomized trial
43. Control of emesis by a low dose of ondansetron and dexamethasone
44. Ondansetron for nausea and vomiting associated with moderately emetogenic cancer chemotherapy
45. Oral treatment with ondansetron in an outpatient setting
46. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy
47. Ondansetron tablet plus dexamethasone in the prophylaxis of acute emesis and nausea associated with low or high dose cisplatin-based chemotherapy in lung cancer: Double-blind comparative, consecutive study
48. Ondansetron for the control of dacarbazine-induced emesis
49. Survey ranking of emetogenic control in children receiving chemotherapy
50. 2
51. Assessment of chemotherapy induced emesis and evaluation of a reduceddose intravenous ondansetron regimen in pediatric outpatients with leukemia
52. Assessment of the emetogenic potential of intrathecal chemotherapy and response to prophylactic treatment with ondansetron
53. Granisetron: A review of its pharmacological properties and therapeutic use as an antiemetic
54. Granisetron: An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy
55. Efficacy and safety of granisetron, a selective 5 hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin
56. Granisetron Study Group Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy
57. Intravenous (IV) granisetron vs ondansetron in the prevention of cyclophosphamide-doxorubicin-induced emesis in breast cancer patients: A double-blind crossover study
58. Granisetron Study Group. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis
59. Intravenous granisetron - Establishing the optimal dose
60. Granisetron Study Group. A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin
61. Granisetron Study Group. A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy
62. Granisetron Study Group. A comparison of granisetron as a single agent with conventional combination antiemetic therapies in the treatment of cytostatic-induced emesis
63. Italian Group for Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis
64. Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: A dose-ranging study
65. Comparison of the efficacy of oral granisetron alone and with dexamethasone: A conventional antiemetic treatment for the prevention of nausea and vomiting for 24 hours following cisplatin treatment
66. Oral granisetron alone and in combination with dexamethasone: A double-blind, randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group
67. A unique, all-oral, single-dose, combination antiemetic regimen with high efficacy and marked cost-savings potential
68. Low dose oral granisetron (1mg) plus intravenous dexamethasone: Efficacy in gynecologic cancer patients receiving carboplatin-based chemotherapy
69. Efficacy of a single 1-mg OR 2-mg dose of oral granisetron for the prevention of nausea and vomiting induced by IV cyclophosphamide or carboplatinbased chemotherapy regimens
70. Single-dose 1mg oral granisetron is less costly and as effective as intravenous ondansetron in controlling nausea and vomiting from moderately emetogenic chemotherapy
71. Pilot studies with oral granisetron in cisplatin-treated patients
72. Comparison of single dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: A multicenter, double-blind, randomized parallel study
73. Single dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy
74. Efficacy and safety of granisetron in the prevention of chemotherapy-induced emesis in paediatric patients
75. A double-blind doseranging study of IV granisetron in children undergoing highly emetogenic chemotherapy
76. Effects of granisetron in children undergoing high-dose chemotherapy: A multi-institutional, cross-over study
77. Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high dose cisplatin
78. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin induced emesis in patients with cancer
79. A double blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesylate and granisetron in patients receiving high dose cisplatin chemotherapy
80. Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting. Pooled analysis of 14 clinical trials
81. Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy
82. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy
83. Prevention of acute emesis in cancer patients following high dose cisplatin with the combination of oral dolasetron and dexamethasone
84. Open label IV dolasetron mesylate in pediatric patients receiving moderately to highly emetogenic chemotherapy: Pharmacokinetics, efficacy and safety
85. Open label oral dolasetron mesylate in pediatric patients receiving moderately to highly emetogenic chemotherapy: Pharmacokinetics, efficacy and safety
86. Ondansetron: Costs and resource utilisation in a US teaching hospital setting
87. The real cost of emesis - An economic analysis of ondansetron vs metoclopramide in controlling emesis in patients receiving chemotherapy for cancer
88. Ondansetron: A cost-effective advance in antiemetic therapy
89. The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy-induced emesis
90. Pharmacoeconomic analysis of prophylactic treatments for emesis secondary to breast cancer chemotherapy
91. Application of pharmacoeconomics to develop and justify drug use guidelines
92. Assuring the optimal use of serotonin antagonist antiemetics: Process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center
93. Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy
94. Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer
95. Cost effectiveness of 5-hydroxytryptamine-3 receptor antagonists: A retrospective comparison of ondansetron and granisetron
96. 5-HT3-receptor antagonists in the management of emesis: Pharmacoeconomic issues
97. Economic evaluation of ondansetron: Preliminary analysis using clinical trial data prior to price setting
98. The antiemetic efficacy and cost-benefit ratio of ondansetron calculated with a new health approach to health technology assessment (real costbenefit index)
99. Cost-effective use of antiemetics
100. Quality of life consequences of chemotherapy-induced emesis
101. Results of a compassionate use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy
102. Measurement of quality of life in clinical trials
103. Impact of nausea/vomiting on quality of life as a visual analogue scale-derived utility score
104. American Society of Health-System Pharmacists (ASHP) Commission on Therapeutics ASHP Therapeutic Guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery
105. Pharmaceutical care in oncology. Clinical brief number 1; antiemetic therapy
106. Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration
107. Recommendations for the use of antiemetics: Evidence-based clinical practice guidelines